|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CYP2C8-MTG2 (FusionGDB2 ID:HG1558TG26164) |
Fusion Gene Summary for CYP2C8-MTG2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CYP2C8-MTG2 | Fusion gene ID: hg1558tg26164 | Hgene | Tgene | Gene symbol | CYP2C8 | MTG2 | Gene ID | 1558 | 26164 |
| Gene name | cytochrome P450 family 2 subfamily C member 8 | mitochondrial ribosome associated GTPase 2 | |
| Synonyms | CPC8|CYP2C8DM|CYPIIC8|MP-12/MP-20 | GTPBP5|ObgH1|dJ1005F21.2 | |
| Cytomap | ('CYP2C8')('MTG2') 10q23.33 | 20q13.33 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cytochrome P450 2C8P450 form 1cytochrome P450 IIC2cytochrome P450 MP-12cytochrome P450 MP-20cytochrome P450 form 1cytochrome P450, family 2, subfamily C, polypeptide 8cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8flavopr | mitochondrial ribosome-associated GTPase 2GTP binding protein 5 (putative)GTP-binding protein 5protein obg homolog 1 | |
| Modification date | 20200320 | 20200313 | |
| UniProtAcc | P10632 | . | |
| Ensembl transtripts involved in fusion gene | ENST00000371270, ENST00000535898, ENST00000539050, | ||
| Fusion gene scores | * DoF score | 1 X 1 X 1=1 | 2 X 2 X 2=8 |
| # samples | 1 | 2 | |
| ** MAII score | log2(1/1*10)=3.32192809488736 | log2(2/8*10)=1.32192809488736 | |
| Context | PubMed: CYP2C8 [Title/Abstract] AND MTG2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CYP2C8(96827516)-MTG2(60778200), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CYP2C8 | GO:0002933 | lipid hydroxylation | 14559847 |
| Hgene | CYP2C8 | GO:0006082 | organic acid metabolic process | 19651758 |
| Hgene | CYP2C8 | GO:0008202 | steroid metabolic process | 14559847 |
| Hgene | CYP2C8 | GO:0008210 | estrogen metabolic process | 12865317|14559847 |
| Hgene | CYP2C8 | GO:0017144 | drug metabolic process | 19651758 |
| Hgene | CYP2C8 | GO:0019373 | epoxygenase P450 pathway | 7574697 |
| Hgene | CYP2C8 | GO:0042573 | retinoic acid metabolic process | 11093772 |
| Hgene | CYP2C8 | GO:0042738 | exogenous drug catabolic process | 18619574 |
| Hgene | CYP2C8 | GO:0046456 | icosanoid biosynthetic process | 15766564 |
| Hgene | CYP2C8 | GO:0055114 | oxidation-reduction process | 19651758 |
| Hgene | CYP2C8 | GO:0070989 | oxidative demethylation | 18619574 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Top |
Fusion Gene ORF analysis for CYP2C8-MTG2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CYP2C8-MTG2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for CYP2C8-MTG2 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:96827516/:60778200) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CYP2C8 | . |
| FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed:7574697, PubMed:15766564, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed:11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed:14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed:26427316). {ECO:0000269|PubMed:11093772, ECO:0000269|PubMed:14559847, ECO:0000269|PubMed:15766564, ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:26427316, ECO:0000269|PubMed:7574697}. | FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CYP2C8-MTG2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for CYP2C8-MTG2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CYP2C8-MTG2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | CYP2C8 | P10632 | DB03796 | Palmitic Acid | Small molecule | Approved | |
| Hgene | CYP2C8 | P10632 | DB00951 | Isoniazid | Small molecule | Approved|Investigational |
Top |
Related Diseases for CYP2C8-MTG2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CYP2C8 | C4693948 | DRUG METABOLISM, ALTERED, CYP2C8-RELATED | 2 | ORPHANET |
| Hgene | CYP2C8 | C0013221 | Drug toxicity | 1 | CTD_human |
| Hgene | CYP2C8 | C0022658 | Kidney Diseases | 1 | CTD_human |
| Hgene | CYP2C8 | C0023452 | Childhood Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Hgene | CYP2C8 | C0023453 | L2 Acute Lymphoblastic Leukemia | 1 | CTD_human |
| Hgene | CYP2C8 | C0027765 | nervous system disorder | 1 | CTD_human |
| Hgene | CYP2C8 | C0035410 | Rhabdomyolysis | 1 | CTD_human |
| Hgene | CYP2C8 | C0041755 | Adverse reaction to drug | 1 | CTD_human |
| Hgene | CYP2C8 | C1832733 | Rhabdomyolysis, Cerivastatin-Induced | 1 | GENOMICS_ENGLAND |
| Hgene | CYP2C8 | C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 1 | CTD_human |
| Hgene | CYP2C8 | C2239176 | Liver carcinoma | 1 | CTD_human |
| Hgene | CYP2C8 | C4721453 | Peripheral Nervous System Diseases | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies